Danaher Corporation (DHR)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $163.94B
Last updated: Nov 17, 2026 at 11:04 AM ET
Danaher Corporation (DHR) Earnings: Report Dates and Results
Danaher (DHR) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, Danaher reported EPS of $2.11, above the $1.92 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DHR has an expected report date of Jan 26, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 12.1% above the $2.23 reported for the quarter ended Dec 31, 2025.
DHR Earnings Call
The latest DHR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, DHR beat 39 and missed 1. Revenue for the quarter ended Sep 30, 2026 was $6.55B, up 8.3% from $6.05B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.11 | $1.92 | $1.90 - $1.99 | +9.90% | Beat | +11.6% | 20 | N/A | Oct 21, 2026 | $6.55B |
| Jun 30, 2026 | $1.94 | $1.84 | $1.83 - $1.86 | +5.43% | Beat | +7.8% | 5 | 2 up, 0 down | Jul 21, 2026 | $6.26B |
| Mar 31, 2026 | $2.06 | $1.94 | $1.91 - $1.96 | +6.19% | Beat | +9.6% | 20 | 1 up, 2 down | Apr 21, 2026 | $5.95B |
| Dec 31, 2025 | $2.23 | $2.19 | $2.14 - $2.24 | +1.83% | Beat | +4.2% | 11 | 3 up, 0 down | Jan 28, 2026 | $6.84B |
| Sep 30, 2025 | $1.89 | $1.72 | $1.69 - $1.78 | +9.88% | Beat | +10.5% | 19 | 3 up, 2 down | Oct 21, 2025 | $6.05B |
| Jun 30, 2025 | $1.80 | $1.64 | $1.62 - $1.66 | +9.76% | Beat | +4.7% | 21 | 0 up, 1 down | Jul 22, 2025 | $5.94B |
| Mar 31, 2025 | $1.88 | $1.64 | $1.56 - $1.97 | +14.63% | Beat | -2.1% | 22 | 3 up, 2 down | Apr 22, 2025 | $5.74B |
| Dec 31, 2024 | $2.14 | $2.16 | $2.11 - $2.22 | -0.93% | Miss | +2.4% | 22 | 5 up, 2 down | Jan 29, 2025 | $6.54B |
| Sep 30, 2024 | $1.71 | $1.57 | $1.53 - $1.70 | +8.92% | Beat | -15.3% | 22 | 5 up, 0 down | Oct 22, 2024 | $5.80B |
| Jun 30, 2024 | $1.72 | $1.57 | $1.55 - $1.64 | +9.55% | Beat | -16.1% | 20 | 1 up, 2 down | Jul 23, 2024 | $5.74B |
| Mar 31, 2024 | $1.92 | $1.71 | N/A | +12.28% | Beat | -18.6% | 20 | 2 up, 1 down | Apr 23, 2024 | $5.80B |
| Dec 31, 2023 | $2.09 | $1.91 | $1.66 - $1.98 | +9.42% | Beat | -27.2% | 20 | 5 up, 0 down | Jan 30, 2024 | $6.41B |
| Sep 30, 2023 | $2.02 | $1.88 | $1.54 - $2.02 | +7.45% | Beat | -21.1% | 19 | 2 up, 0 down | Oct 24, 2023 | $5.62B |
| Jun 30, 2023 | $2.05 | $2.02 | N/A | +1.49% | Beat | -25.7% | 21 | 1 up, 1 down | Jul 25, 2023 | $5.91B |
| Mar 31, 2023 | $2.36 | $2.26 | $2.20 - $2.28 | +4.42% | Beat | -14.5% | 20 | 1 up, 0 down | Apr 25, 2023 | $5.95B |
| Dec 31, 2022 | $2.87 | $2.55 | $2.35 - $2.84 | +12.55% | Beat | +6.7% | 21 | 9 up, 1 down | Jan 24, 2023 | $3.54B |
| Sep 30, 2022 | $2.56 | $2.25 | $2.20 - $2.41 | +13.78% | Beat | +7.1% | 20 | 4 up, 1 down | Oct 20, 2022 | $7.66B |
| Jun 30, 2022 | $2.76 | $2.34 | $2.29 - $2.50 | +17.95% | Beat | +12.2% | 18 | 0 up, 0 down | Jul 21, 2022 | $7.75B |
| Mar 31, 2022 | $2.76 | $2.66 | $2.44 - $2.80 | +3.76% | Beat | +9.5% | 18 | 3 up, 0 down | Apr 21, 2022 | $7.69B |
| Dec 31, 2021 | $2.69 | $2.54 | $2.39 - $2.73 | +5.91% | Beat | +29.3% | 19 | 8 up, 0 down | Jan 27, 2022 | $3.50B |
| Sep 30, 2021 | $2.39 | $2.15 | $1.99 - $2.30 | +11.16% | Beat | +39.0% | 18 | N/A | Oct 21, 2021 | $7.23B |
| Jun 30, 2021 | $2.46 | $2.05 | $1.97 - $2.15 | +20.00% | Beat | +70.8% | 18 | N/A | Jul 22, 2021 | $7.22B |
| Mar 31, 2021 | $2.52 | $1.77 | $1.59 - $2.09 | +42.37% | Beat | +140.0% | 18 | N/A | Apr 22, 2021 | $6.86B |
| Dec 31, 2020 | $2.08 | $1.88 | $1.77 - $2.03 | +10.64% | Beat | +62.5% | 19 | N/A | Jan 28, 2021 | $6.76B |
| Sep 30, 2020 | $1.72 | $1.36 | $1.30 - $1.45 | +26.47% | Beat | +48.3% | 16 | N/A | Oct 22, 2020 | $5.88B |
| Jun 30, 2020 | $1.44 | $1.09 | $0.90 - $1.25 | +32.11% | Beat | +21.0% | 15 | N/A | Jul 23, 2020 | $5.30B |
| Mar 31, 2020 | $1.05 | $1.02 | $0.69 - $1.08 | +2.94% | Beat | -1.9% | 11 | N/A | May 6, 2020 | $4.34B |
| Dec 31, 2019 | $1.28 | $1.25 | $1.24 - $1.28 | +2.40% | Beat | 0.0% | 11 | N/A | Jan 30, 2020 | $4.87B |
| Sep 30, 2019 | $1.16 | $1.15 | $1.13 - $1.17 | +0.87% | Beat | +5.5% | 15 | N/A | Oct 24, 2019 | $4.38B |
| Jun 30, 2019 | $1.19 | $1.16 | $1.14 - $1.18 | +2.59% | Beat | +3.5% | 17 | N/A | Jul 18, 2019 | $4.44B |
| Mar 31, 2019 | $1.07 | $1.02 | $0.98 - $1.03 | +4.90% | Beat | +8.1% | 15 | N/A | Apr 18, 2019 | $4.22B |
| Dec 31, 2018 | $1.28 | $1.27 | $1.25 - $1.28 | +0.79% | Beat | +7.6% | 18 | N/A | Jan 29, 2019 | $2.52B |
| Sep 30, 2018 | $1.10 | $1.08 | $1.05 - $1.10 | +1.85% | Beat | +10.0% | 17 | N/A | Oct 18, 2018 | $4.85B |
| Jun 30, 2018 | $1.15 | $1.09 | $1.06 - $1.10 | +5.50% | Beat | +16.2% | 17 | N/A | Jul 19, 2018 | $4.98B |
| Mar 31, 2018 | $0.99 | $0.94 | $0.91 - $0.96 | +5.32% | Beat | +16.5% | 16 | N/A | Apr 19, 2018 | $4.70B |
| Dec 31, 2017 | $1.19 | $1.16 | $1.14 - $1.18 | +2.59% | Beat | +13.3% | 17 | N/A | Jan 30, 2018 | $2.27B |
| Sep 30, 2017 | $1.00 | $0.95 | $0.94 - $0.96 | +5.26% | Beat | +14.9% | 15 | N/A | Oct 19, 2017 | $4.53B |
| Jun 30, 2017 | $0.99 | $0.97 | $0.95 - $0.98 | +2.06% | Beat | -20.8% | 16 | N/A | Jul 20, 2017 | $4.51B |
| Mar 31, 2017 | $0.85 | $0.84 | N/A | +1.19% | Beat | -21.3% | N/A | N/A | Apr 20, 2017 | $4.21B |
| Dec 31, 2016 | $1.05 | $1.03 | N/A | +1.94% | Beat | -17.3% | N/A | N/A | Jan 31, 2017 | $4.58B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $7.80, up 4.1% from the year before. It was $4.25 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $7.80 | +4.1% |
| Dec 31, 2024 | $7.49 | -12.1% |
| Dec 31, 2023 | $8.52 | -22.2% |
| Dec 31, 2022 | $10.95 | +8.8% |
| Dec 31, 2021 | $10.06 | +59.9% |
| Dec 31, 2020 | $6.29 | +33.8% |
| Dec 31, 2019 | $4.70 | +4.0% |
| Dec 31, 2018 | $4.52 | +12.2% |
| Dec 31, 2017 | $4.03 | -5.2% |
| Dec 31, 2016 | $4.25 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,444 | 11 | |
| 2026Q2 | Jun 30, 2026 | 7,503 | 13 | |
| 2026Q1 | Mar 31, 2026 | 7,397 | 12 | |
| 2025Q4 | Dec 31, 2025 | 7,385 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,614 | 11 | |
| 2025Q2 | Jun 30, 2025 | 7,946 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,246 | 13 | |
| 2024Q4 | Dec 31, 2024 | 7,006 | 11 |
2026Q3 Earnings Call
Opening remarks
Rachel Vatnsdal Vice President of Investor Relations Good morning, everyone, and thanks for joining us on the call. With us today are Julie Sawyer Montgomery, our President and Chief Executive Officer, and Matt Gugino, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, quarterly report on Form 10-Q, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call, and a note containing details of historical and anticipated future financial performance are all available in the investors section of our website, www.danaher.com, under the heading Quarterly Earnings. The audio portion of this call will be archived in the investors section of our website later today under the heading Events and Presentations and will remain archived until our next quarterly call. A dial-in replay of this call will also be available until November 4th, 2026. During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. Our Form 10-Q and the supplemental materials I referenced describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to results from continuing operations in the third quarter of 2026, and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices that have applications submitted and pending for certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of our federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements except as required by law. With that, I'd like to turn the call over to Julie.
Julie Sawyer Montgomery President and Chief Executive Officer Thank you, Rachel, and good morning, everyone. Before we get into the quarter, I'd like to share my perspective on Danaher today and the opportunity ahead as I begin this next chapter as CEO. The opportunity for Danaher is straightforward: to become the defining leader in Life Sciences and Diagnostics, a company that unambiguously gains share, delivers sustainable, profitable growth, and helps our customers improve outcomes for patients around the world. The foundation we built at Danaher is strong.
Frequently Asked Questions About DHR
When is Danaher's next earnings date?
Danaher's next earnings report is expected for Jan 26, 2027.
Did DHR beat earnings estimates last quarter?
Yes. Danaher reported EPS of $2.11 for the quarter ended Sep 30, 2026, above the $1.92 estimate, a 9.90% surprise.
What EPS do analysts expect from DHR next quarter?
The consensus EPS estimate for Danaher for the quarter ending Dec 31, 2026 is $2.50 from 23 analysts, with estimates from $2.42 to $2.63.
How often does DHR beat earnings estimates?
Danaher beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +7.09%.
DHR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts